Last reviewed · How we verify
[14C]-GSK3640254 intravenous infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-GSK3640254 intravenous infusion ([14C]-GSK3640254 intravenous infusion) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-GSK3640254 intravenous infusion TARGET | [14C]-GSK3640254 intravenous infusion | ViiV Healthcare | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-GSK3640254 intravenous infusion CI watch — RSS
- [14C]-GSK3640254 intravenous infusion CI watch — Atom
- [14C]-GSK3640254 intravenous infusion CI watch — JSON
- [14C]-GSK3640254 intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-GSK3640254 intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-gsk3640254-intravenous-infusion. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab